RUNX1 and acute lymphoblastic leukemia: Although t(1;19)(q23;p13) was initially associated with poor prognosis in pediatric BCP-ALL, the recent development of intensified chemotherapy regimens has improved the outcome of this subgroup, resulting in a 5-year event-free survival (EFS) rate of ∼85−90% in western countries, which is similar to that of TEL-AML1 positive or high hyperdiploid BCP-ALL 2,4–6.